Y-mAbs Therapeutics 2025 Q2 Earnings Narrowed Losses and Pending Acquisition

Y-mAbs Therapeutics (YMAB) reported its fiscal 2025 Q2 earnings on August 8, 2025, posting narrowed losses and exceeding its revenue guidance. The company reported a significant 65% reduction in its net loss to -$3.24 million from -$9.25 million in the prior year, with a 66.7% improvement in loss per share to -$0.07. Total revenue for the quarter stood at $19.52 million, falling short of the prior year by 14.4%.

The total revenue of Y-mAbs Therapeutics decreased by 14.4% to $19.52 million in 2025 Q2, down from $22.80 million in 2024 Q2. This decline was driven by a notable decrease in net product revenue, which fell to $19.02 million, compared to its license revenue of $500,000, contributing to the total revenue of $19.52 million for the quarter.

Y-mAbs Therapeutics narrowed losses to $0.07 per share in 2025 Q2 from a loss of $0.21 per share in 2024 Q2, representing a 66.7% improvement. Meanwhile, the company successfully narrowed its net loss to $-3.24 million in 2025 Q2, reducing losses by 65.0% compared to the $-9.25 million net loss reported in 2024 Q2. This marked progress in the company’s cost management and operational efficiency.

The stock price of Y-mAbs Therapeutics has edged down 0.00% during the latest trading day, has surged 87.86% during the most recent full trading week, and has surged 91.67% month-to-date.

Post-earnings price action for Y-mAbs Therapeutics shows that a strategy of buying shares after a revenue raise quarter-over-quarter on the financial report released date and holding for 30 days resulted in no return over the past three years. The strategy had a CAGR of 0.00% and an excess return of -4.09%, underperforming the benchmark by a significant margin. Additionally, the strategy had a maximum drawdown of 0.00% and a Sharpe ratio of 0.00%, indicating a risk-free but also a riskless scenario.

Y-mAbs President and CEO, David A. Pincock, highlighted the Company’s financial performance for the second quarter of 2025, noting total revenues of $19.5 million, exceeding guidance of $17–$19 million. Despite a 14% year-over-year decline in total revenues, driven by lower DANYELZA net product sales both in the U.S. and internationally, the CEO emphasized the importance of the pending acquisition by SERB Pharmaceuticals, which he described as a transformative opportunity for stockholders. With the transaction expected to close by year-end 2025, the Company’s strategic focus has shifted to executing the merger process, aligning with the Board’s unanimous approval and SERB’s obligation to commence the tender offer by August 19, 2025.

The Company expects the acquisition by SERB to close by the fourth quarter of 2025, contingent on customary conditions and regulatory approvals, including the Hart-Scott-Rodino Antitrust Act waiting period. SERB is required to begin a cash tender offer of $8.60 per share, representing a 105% premium to Y-mAbs’ closing price on August 4, 2025. The Company will not hold a webcast or conference call to discuss its Q2 2025 results due to the pending transaction. No additional financial guidance was provided beyond the Q2 2025 revenue performance and expectations related to the acquisition.

The recent developments around Y-mAbs Therapeutics include a pending acquisition by SERB Pharmaceuticals. The acquisition is expected to close by the fourth quarter of 2025, subject to customary conditions and regulatory approvals. SERB is mandated to begin a cash tender offer of $8.60 per share, a 105% premium over Y-mAbs’ closing price on August 4, 2025. The Board of Directors has approved the transaction, and SERB must initiate the tender offer by August 19, 2025. The Company’s CEO emphasized the transformative potential of the acquisition for stockholders, despite the 14% year-over-year decline in total revenues due to lower DANYELZA sales.

The acquisition marks a pivotal shift in the Company’s strategic focus from ongoing operations to executing the merger process. No conference call or webcast will be held to discuss Q2 2025 results, as the Company remains fully engaged in the acquisition process. Additional financial guidance has not been provided beyond the Q2 performance and the acquisition timeline.